Research Information Only — Educational content, not medical advice. GH-axis peptides require physician supervision, IGF-1 monitoring, and cancer-history caution.
PeptideReport.ai
Compounds › Tesamorelin

Compound Profile · GH Axis

Tesamorelin

Of all the growth-hormone-axis peptides, this is the one with a specific reputation: visceral fat — the deep, metabolically nasty belly fat that sits around the organs. That focus is what earns tesamorelin its own lane. Here's what it is, how it differs from its cousins, and where the cautions bite.

GHRH AnalogVisceral FatGH AxisIGF-1 Monitoring
The Peptide Evidence Index
See how all 34 peptides rank by the strength of real human evidence — one honest scorecard.
View the Index →

What It Is

A growth-hormone-releasing hormone analog

Tesamorelin is a GHRH analog — it works upstream, prompting the pituitary to release the body's own growth hormone in the natural, pulsatile way. That places it firmly in the secretagogue family alongside sermorelin and CJC-1295: none of these inject growth hormone; they nudge your own. What sets tesamorelin apart is the body of attention on one outcome specifically — reduction of visceral adipose tissue, the deep belly fat linked to metabolic risk.

Why It Stands Out

The visceral-fat angle

Belly fat comes in two flavors: the subcutaneous fat you can pinch, and the visceral fat packed around the organs that's far more metabolically harmful. Tesamorelin's distinguishing feature is its attention on that visceral compartment, which is why it comes up for central adiposity when a GH-axis approach is being considered. That's a meaningfully different pitch from "GH peptide for recovery and sleep," and it's why tesamorelin isn't interchangeable with the others.

The comparisonSermorelin — the gentle entry secretagogue. CJC-1295 + ipamorelin — the workhorse pairing for sleep, recovery, body composition. Tesamorelin — the one with a visceral-fat focus. Same family, different emphasis. See tesamorelin vs. CJC-1295.

The Cautions

Same GH-axis rules apply

Non-negotiablesBecause it acts on the GH/IGF-1 pathway, tesamorelin carries the family's cautions: IGF-1 should be monitored, and personal or family cancer history is a specific reason for caution, since this is a growth pathway. Blood sugar and insulin sensitivity can be affected too, which matters for anyone managing glucose. This is physician-managed, and research-grade material needs a certificate of analysis. See the GH axis chapter.

Common Questions

Tesamorelin, answered

What is tesamorelin?
A GHRH analog that prompts your own pituitary to release growth hormone, in the secretagogue family with sermorelin and CJC-1295. It's distinguished by attention on visceral (deep belly) fat.
How is it different from other GH peptides?
Same secretagogue mechanism, different emphasis — tesamorelin has the most attention on visceral fat specifically, where CJC-1295 + ipamorelin lean toward sleep, recovery, and body composition.
Is it safe?
It requires physician supervision, IGF-1 monitoring, and cancer-history caution because it acts on a growth pathway. It can affect blood sugar. Sourcing needs a certificate of analysis.
Does it target belly fat?
Its distinguishing attention is on visceral adipose tissue — the deep, metabolically harmful belly fat — rather than the subcutaneous fat you can pinch. It's physician-managed within a plan, not a spot-reduction shortcut.

About the Author

SD
Dr. Scott DelBoccio, DMD
Founding Author · PeptideReport.ai

Dr. DelBoccio is a clinician with thirty years of practice and a focus on peptide pharmacology and metabolic health. PeptideReport.ai is the clinician-authored, education-only reference the peptide space lacked. No products are sold on this site.

Full Disclaimer

This page is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. The compounds discussed are research/investigational and require physician supervision. PeptideReport.ai does not manufacture, sell, or endorse any preparation. Content addresses adults 21 and older. Evidence and regulatory status continue to evolve.